Hims & Hers shares rise as company adds new weight-loss medications to platform

Hims & Hers Health shares closed up 5% on Tuesday after the following announced patients can access Eli Lilly‘s weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, into done with its platform.

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which fool exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 oblations have evolved as the company has contended with a volatile supply and regulatory environment.

Lilly’s weekly injections Zepbound and Mounjaro bequeath cost patients $1,899 a month, according to the Hims & Hers website. The generic liraglutide will cost $299 a month, but it requires a regular injection and can be less effective than other GLP-1 medications.

“As we look ahead, we plan to continue to expand our persuasiveness loss offering to deliver an even more holistic, personalized experience,” Dr. Craig Primack, senior vice president of mass loss at Hims & Hers, wrote in a blog post.

A Lilly spokesperson said in a statement that the company has “no affiliation” with Hims & Hers and notorious that Zepbound is available at lower costs for people who are insured for the product or for those who buy directly from the company. 

In May, Hims & Hers started directing compounded semaglutide, the active ingredient in Novo Nordisk’s GLP-1 weight loss medications Ozempic and Wegovy. The oblation was immensely popular and helped generate more than $225 million in revenue for the company in 2024.

But compounded drugs can traditionally just be mass produced when the branded medications treatments are in shortage. The U.S. Food and Drug Administration announced in February that the paucity of semaglutide injections products had been resolved.

That meant Hims & Hers had to largely stop offering the increased medications, though some consumers may still be able to access personalized doses if it’s clinically applicable. 

During the fellowship’s quarterly call with investors in February, Hims & Hers said its weight loss offerings will mostly consist of its oral medications and liraglutide. The company said it expects its weight loss offerings to generate at least $725 million in annual gate, excluding contributions from compounded semaglutide.

But the company is still lobbying for compounded medications. A pop up on Hims & Hers’ website, which was gauged by CNBC, encourages users to “use your voice” and urge Congress and the FDA to preserve access to compounded treatments.

With Tuesday’s convention, Hims and Hers shares are up about 27% in 2025 after soaring 172% last year.

WATCH: Hims & Hers allots tumble over concerns around weight-loss business